|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/404 | (2006.01) |
| A61K 31/404 | (2013.01) | ||
| A61P 37/00 | (2006.01) | ||
| A61P 37/00 | (2018.01) |
| (11) | Number of the document | 3908276 |
| (13) | Kind of document | T |
| (96) | European patent application number | 20703633.6 |
| Date of filing the European patent application | 2020-01-08 | |
| (97) | Date of publication of the European application | 2021-11-17 |
| (45) | Date of publication and mention of the grant of the patent | 2025-06-11 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2020/012783 |
| Date | 2020-01-08 |
| (87) | Number | WO 2020/146529 |
| Date | 2020-07-16 |
| (30) | Number | Date | Country code |
| 201962789937 P | 2019-01-08 | US |
| (72) |
NAIK, Snehal , US
|
| (73) |
Arena Pharmaceuticals, Inc. ,
66 Hudson Boulevard East, New York, NY 10001-2192,
US
|
| (54) | METHODS OF TREATING CONDITIONS RELATED TO THE S1P1 RECEPTOR |
| METHODS OF TREATING CONDITIONS RELATED TO THE S1P1 RECEPTOR |